Scarica l'app Stockscreener
14.60
3.69%
-0.56
Pre-mercato:
15.41
0.81
+5.55%
Precedente Chiudi:
$15.16
Aprire:
$15.24
Volume 24 ore:
1.15M
Relative Volume:
1.39
Capitalizzazione di mercato:
$1.55B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-4.7249
EPS:
-3.09
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
+9.36%
1M Prestazione:
+24.57%
6M Prestazione:
+94.67%
1 anno Prestazione:
-14.62%
Intervallo 1D:
$14.26
$15.24
Intervallo di 1 settimana:
$13.61
$16.12
Portata 52W:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Confronta RCUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
14.60 | 1.61B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Why Arcus Biosciences Inc. stock is rated strong buy2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
Arcus Biosciences (RCUS) Reveals Promising Phase 2 Gastric Cance - GuruFocus
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ - Stocktwits
Arcus Biosciences to present promising gastric cancer survival data - Investing.com
Arcus Biosciences Shows 26.7‑Month Median OS in EDGE‑Gastric | RCUS Stock News - Stock Titan
Will Arcus Biosciences Inc. stock benefit from sector rotationJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Price momentum metrics for Arcus Biosciences Inc. explainedWeekly Trend Summary & AI Driven Price Predictions - newser.com
Arcus Biosciences (NYSE:RCUS) COO Jennifer Jarrett Sells 37,792 Shares of Stock - MarketBeat
60,300 Options at $15.05 — Arcus Biosciences Grants 30,150 RSUs under 2020 Inducement Plan - Stock Titan
Arcus Biosciences Hits Day High with Strong 7.27% Intraday Surge - Markets Mojo
Arcus Biosciences Hits Day High with Strong 8.46% Intraday Surge - Markets Mojo
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data By Investing.com - Investing.com Australia
Arcus Biosciences COO Jarrett sells $750k in shares By Investing.com - Investing.com Canada
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data - Investing.com India
Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? - MSN
Weiss Ratings Reaffirms "Sell (D-)" Rating for Arcus Biosciences (NYSE:RCUS) - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Arcus Biosciences stock By Investing.com - Investing.com Canada
RCUS: Truist Securities Raises Price Target for Arcus Biosciences | RCUS Stock News - GuruFocus
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment - inkl
A Fresh Look at Arcus Biosciences (RCUS) Valuation After New Casdatifan Data and Expanded Pipeline Initiatives - Yahoo Finance
Arcus Biosciences announces new anti-inflammation programs - BioWorld MedTech
Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating - MarketScreener
Arcus Biosciences Presents Promising ARC-20 Study Data - MSN
Why Is Arcus Biosciences Stock Trading Higher On Monday? - Sahm
Arcus Biosciences (NYSE:RCUS) Trading Up 15.2%Here's What Happened - MarketBeat
Transcript : Arcus Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Arcus Biosciences (RCUS) Sees Promising Results in Latest Study - GuruFocus
Arcus Biosciences (RCUS) Shares Positive Data on Casdatifan for Metastatic RCC - GuruFocus
Arcus Biosciences presents new data for its HIF-2a inhibitor casdatifan - MarketScreener
Arcus Biosciences reports positive casdatifan data, expands into inflammation - StreetInsider
Can momentum traders help lift Arcus Biosciences Inc.Weekly Stock Recap & Weekly High Return Forecasts - newser.com
What drives Arcus Biosciences Inc stock priceSector Performance Drivers & Free Superior Stock Performance - earlytimes.in
How to use Fibonacci retracement on Arcus Biosciences Inc.Trade Analysis Summary & Safe Capital Allocation Plans - newser.com
Published on: 2025-10-05 02:17:26 - newser.com
Pleasing Signs As A Number Of Insiders Buy Arcus Biosciences Stock - simplywall.st
Technical analysis overview for Arcus Biosciences Inc. stockJuly 2025 Catalysts & Weekly Momentum Picks - newser.com
Arcus Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Arcus Biosciences Hits Day High with 9.94% Surge in Strong Intraday Performance - Markets Mojo
Barclays Keeps Their Buy Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,831 Shares - MarketBeat
Published on: 2025-09-30 20:31:22 - newser.com
Insider Sell: Alexander Azoy Sells Shares of Arcus Biosciences I - GuruFocus
What analysts say about Arcus Biosciences Inc stockIndustrial Stocks Review & Big Profit Small Investment - earlytimes.in
Arcus Biosciences Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Arcus Biosciences Inc Stock Analysis and ForecastMarket Rumors and News & Affordable Investment Strategies - earlytimes.in
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arcus Biosciences Inc Azioni (RCUS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jarrett Jennifer | Chief Operating Officer |
Oct 06 '25 |
Option Exercise |
1.23 |
12,500 |
15,345 |
226,732 |
| Jarrett Jennifer | Chief Operating Officer |
Oct 08 '25 |
Sale |
15.05 |
37,792 |
568,611 |
214,232 |
| Jarrett Jennifer | Chief Operating Officer |
Oct 06 '25 |
Sale |
14.54 |
12,500 |
181,801 |
214,232 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):